New Pill Offers Hope Against Pancreatic Cancer
A new pill can reportedly double survival in early pancreatic cancer trials, raising cautious optimism about a disease that has long resisted treatment. Revolution Medicines' daraxonrasib targets KRAS, a gene that supplies instructions for the development of the K-Ras protein which is essentially a switch for controlling cell division, growth, and death. Daraxonrasib belongs to a class of targeted therapies dubbed RAS inhibitors, designed to act on the KRAS gene and disrupt a genetic mutation found across multiple cancer types. The biotech company behind the novel treatment will release its full Phase 3 results at the upcoming American Society of Clinical Oncology meeting. Pancreatic cancer has a…

